Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti–Programmed Death 1 Immunotherapy for Recurrent Liver Tumors

Saved in:
Bibliographic Details
Published inLiver transplantation Vol. 27; no. 3; pp. 444 - 449
Main Authors Shi, Guo‐Ming, Wang, Jiping, Huang, Xiao‐Wu, Huang, Xiao‐Yong, He, Yi‐Feng, Ji, Yuan, Chen, Yi, Wu, Dong, Lu, Jia‐Cheng, Sun, Qi‐Man, Liu, Wei‐Ren, Wang, Ting, Yang, Liu‐Xiao, Hou, Ying‐Yong, Shi, Ying‐Hong, Sun, Jian, Xiao, Yong‐Sheng, Wang, Zheng, Fan, Jia, Bertagnolli, Monica M., Zhou, Jian
Format Journal Article
LanguageEnglish
Published United States Wolters Kluwer Health, Inc 01.02.2021
Subjects
B7-H1 Antigen
Graft rejection
Graft Rejection - prevention & control
Humans
Immunotherapy
Immunotherapy - adverse effects
Liver cancer
Liver Neoplasms - therapy
Liver Transplantation
PD-1 protein
Tumors
Online AccessGet full text

Cover

More Information
Bibliography:This study was supported by National Key R&D Program of China (2019YFC1315800 and 2019YFC1315802), Shanghai Municipal Key Clinical Specialty, the National Natural Science Foundation of China (81972232, 81830102, and 81772578), and the Shanghai Municipal Natural Science Foundation (18410720700).
These authors contributed equally to this work.
Monica M. Bertagnolli has a travel grant with the Chinese Medical Education Association.
Potential conflict of interest: Nothing to report.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Correspondence-1
ISSN:1527-6465
1527-6473
1527-6473
DOI:10.1002/lt.25887